“Latest Stem Cells News”

Transplanting own stem cells into heart of severe angina patients lessens their pain and improves their ability to walk, a new study has revealed.

The largest national stem cell study for heart disease showed that transplant subjects also experienced fewer deaths than those who didn’t receive stem cells.

In the 12-month Phase II, double-blind trial, subjects’ own purified stem cells, called CD34+ cells, were injected into their hearts in an effort to spur the growth of small blood vessels that make up the microcirculation of the heart muscle (…)

He also said that this study provides the first evidence that a person’s own stem cells can be used as a treatment for their heart disease. However, he cautioned that the findings of the 25-site trial with 167 subjects, require verification in a larger, Phase III study.

The stem cell transplant is the first therapy to produce an improvement in severe angina subjects’ ability to walk on a treadmill. Twelve months after the procedure, the transplant subjects were able to double their improvement on a treadmill compared to the placebo group (…)

from http://timesofindia.indiatimes.com/life/health-fitness/health/Your-own-stem-cells-can-help-treat-heart-disease/articleshow/5242519.cms

Incoming search terms:

“For centuries, scientists have known that certain animals can regenerate missing parts of their bodies. Humans actually share this ability with animals like the starfish and the newt. Although we can’t replace a missing leg or a finger, our bodies are constantly regenerating blood, skin, and other tissues.

The identity of the powerful cells that allow us to regenerate some tissues was first revealed when experiments with bone marrow in the 1950s established the existence of stem cells in our bodies and led to the development of bone marrow transplantation, a therapy now widely used in medicine.

This discovery raised hope in the medical potential of regeneration. For the first time in history, it became possible for physicians to regenerate a damaged tissue with a new supply of healthy cells by drawing on the unique ability of stem cells to create many of the body’s specialized cell types (…)”

Read full story clicking here

Incoming search terms:

Viet Nam’s National Hospital of Pediatrics in Ha Noi this morning announced the initial success of its first stem cell therapy treatment of epidermolysis bullosa (EB), making it only the second medical institution in the world to successfully treat this genetic skin disease in this manner.

Children with EB lack a protein that anchors the outer layer of skin to the body, resulting in very fragile skin that peels off with minor friction or trauma. They suffer painful wounds and infections which eventually are fatal.

The four-year-old boy who underwent the bone marrow transplant received tissue taken from his sister, aged 10, on September 16, to stimulate the production of healthy skin cells.

Nguyen Viet Anh had a severe form of EB, which caused his toes to stick to each other and skin to peel off the inside of his mouth, said hospital director Nguyen Thanh Liem.

“It is a very complicated technology but we are happy that the donor’s bone marrow tissue has taken in his body,” he said.

Anh’s white cell count has increased to a normal level 40 days after the transplant from almost zero. The area of affected skin is now only 7 per cent of the body, a big progress from 23 per cent before the transplant.

Incoming search terms:

Doctors hope a Nottinghamshire boy with leukaemia can undergo a stem cell transplant in May.

Roman Cusick, from Calverton, is currently recovering from chemotherapy.

If he is deemed to be well enough, he will receive cells from an umbilical cord from a German donor in a procedure at Sheffield Children’s Hospital.

In February almost 200 people in Calverton helped took part in a saliva test to see if they were a suitable match.

Leukaemia occurs when large numbers of white blood cells take over the bone marrow, leaving the body unable to produce enough normal blood cells.

Incoming search terms:

Health Counselor Board, Javier Alvarez Guisasola, launched on Wednesday a clinical trial coordinated by Professor Margarita Calonge, IOBA’s on cell therapy applied to treat corneal blindness.
This study was coordinated by the IOBA and IBGM to demonstrate the long-term effectiveness of the epithelial stem cell transplantation of the cornea, previously cultivated to restore corneal blindness. Stem cells come from a healthy eye of the patient or family support.

Incoming search terms:

TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated (…)

“We are greatly encouraged by the phase 1 study results which indicates that TG-0054 has the potential to be used alone, not in combination with G- CSF, for allogenic or autologous stem cell transplantation in cancer patients. This should greatly reduce the hospital and other associated cost for such a procedure. Importantly, the activity and safety profile in the phase 1 study will support our future development of TG-0054 in chemosensitization and tissue ischemia, including myocardial infarction, stroke and severe intermittent claudication. Our preclinical animal disease models and the phase 1 study results lend strong support to clinical development for these clinical indications,” said Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen (…)

from http://www.prnewswire.com/news-releases/excellent-stem-cell-mobilization-and-safety-profile-for-tg-0054-62316942.html

Incoming search terms: